BioCardia takes a new and comprehensive approach to heart failure

We are a clinical-stage regenerative medicine company committed to developing novel therapeutics to improve the lives of patients suffering from cardiovascular diseases with large unmet medical needs.

Read More

Discover us

Financials & Filings

Review our corporate financial reports and SEC filings

Press Releases

Read about our latest company milestones

Clinical Trials

If you or a loved one would like to find out if you qualify to participate in our CardiAMP Heart Failure Study
Complete Questionnaire

Product Pipeline

Learn about our product development programs and obtain an at-a-glance view of their current status

Products

Helix Biotherapeutic Delivery System

Morph Access Products

News

11 May

University of Minnesota

Investigational Therapy Exploring Treatment of Heart Failure Seeks to Stimulate Body’s Natural Healing Response
Read More
16 Apr

Saint Joseph Mercy

St. Joseph Mercy Ann Arbor to perform clinical trial using stem cells to treat congestive heart failure
Read More
31 Jan

BioWorld Med Tech

Biocardia wins IDE for cell therapy as treatment for angina
Read More
03 Oct

BioWorld Med Tech

Biocardia presses on with Cardiamp pivotal trial to treat patients with heart failure
Read More
26 May

Med Latest

BioCardia® Helix Results in Higher Stem Cell Retention in Myocardium
Read More
24 May

Fox 47

UW Health trial involves injecting stem cells into patients with heart failure
Read More
18 Apr

Medical press

First participant treated in trial of stem-cell therapy for heart failure
Read More
05 Mar

Cardiology today

First patient treated in trial of novel cell therapy
Read More
01 Mar

News Center Watch

Johns Hopkins, MSCRF, BioCardia treat first patient with CardiAMP in ischemic heart failure trial
Read More

press releases

11 May
2018 BioCardia, Inc. Reports First Quarter 2018 Financial Results and Business Highlights
10 May
2018 Centers for Medicare and Medicaid Services Approves Reimbursement for BioCardia’s CardiAMP Cell Therapy in Pivotal Clinical Trial Studying Second Indication in Chronic Myocardial Ischemia
25 Apr
2018 BioCardia Receives New Potency Assay Patent, Providing Further Protection to Autologous Cell Therapy Programs in Heart Failure and Refractory Angina
18 Apr
2018 BioCardia Presents at Alliance for Regenerative Medicine’s (ARM’s) Annual Cell & Gene Therapy Investor Day
09 Apr
2018 Phase III CardiAMP Heart Failure Trial Featured in American Heart Journal
21 Mar
2018 BioCardia, Inc. Reports Fourth Quarter 2017 Financial Results and Business Highlights
Have questions?
call us now
: (800) 624-1179
Have questions?
Email us now
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS